10 Pulmonary Hypertension Clinical Trials in Charlottesville, VA (2026)

Q: How do I join a clinical trial in Charlottesville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you.

Recruiting Pulmonary Hypertension Studies in Charlottesville

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

Charlottesville, VAPHASE1329 participantsArvinas Inc.

View Study Details

NCT07054073Recruiting

HCMR Re-Imaging Study

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HC...

Charlottesville, VA314 participantsChristopher Kramer

View Study Details

NCT06704594Recruiting

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle...

Charlottesville, VAPHASE4288 participantsJohns Hopkins University

View Study Details

NCT03161223Recruiting

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

This is an open-label, Phase 1/2a, dose-finding study with an initial phase 1 portion, articulated in four separate treatment arms, followed by a dedicated phase 2 for qualifying treatment Arm(s). Th...

Charlottesville, VAPHASE1148 participantsUniversity of Virginia

View Study Details

NCT04747236Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will ...

Charlottesville, VAPHASE250 participantsUniversity of Virginia

View Study Details

NCT05852717Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Da...

Charlottesville, VAPHASE235 participantsDipenkumar Modi

View Study Details

NCT06175000Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

Charlottesville, VAPHASE228 participantsProvidence Health & Services

View Study Details

NCT03523975Recruiting

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lym...

Charlottesville, VAPHASE128 participantsCity of Hope Medical Center

View Study Details

NCT07003295Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvem...

Charlottesville, VAPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT07264036Recruiting

Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study

Some head and neck cancer survivors develop velopharyngeal dysfunction (VPD), a problem with closure between the soft palate and throat that can cause nasal-sounding speech, food or liquid leaking int...

Charlottesville, VANA20 participantsVanessa Torrecillas

View Study Details

About Pulmonary Hypertension Clinical Trials in Charlottesville

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 10 pulmonary hypertension clinical trials recruiting participants in Charlottesville, VA. These studies are seeking a combined 1,260 participants. Research is being sponsored by Arvinas Inc., Christopher Kramer, Johns Hopkins University and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Charlottesville — FAQ

Are there pulmonary hypertension clinical trials in Charlottesville?

Yes, there are 10 pulmonary hypertension clinical trials currently recruiting in Charlottesville, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlottesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you about next steps.

Are clinical trials in Charlottesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlottesville studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 10 active trials in Charlottesville are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated September 6, 2026 from ClinicalTrials.gov